ROS1 and non-small cell lung carcinoma: Other tyrosine kinase inhibitors (TKIs), including ceritinib [6], lorlatinib [7], and entrectinib [8], have recently shown favorable clinical responses in the ROS1‐rearranged NSCLC patient population, including in patients with brain metastases at baseline [9], thus demonstrating superior blood–brain barrier penetration compared to crizotinib.